Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
BOJ's Ueda warns of global uncertainty, keep markets guessing on next hike
3/10/2025
US government shutdown gives Fed last thing it needs - even less visibility
3/10/2025
Venezuela accuses US of flying combat planes near its coast
3/10/2025
Japan's next leader may be its first woman or youngest in modern era
3/10/2025
Pakistan : Nine killed, four injured in Peshawar bomb blast
3/10/2025
Boeing expands plans to replace striking workers despite senators' calls to end standoff
3/10/2025
